📝 ANG Lifesciences India Ltd — results explained
Quarter ended March 2026 (Q4 FY26)
ANG Lifesciences India Ltd reported revenue of ₹23 crore for the quarter ended March 2026 (Q4 FY26), up 29.0% from ₹18 crore in the same quarter last year, and up 24.6% sequentially over the December 2025 quarter.
The company swung to a net profit of ₹1 crore from a net loss of ₹2 crore a year earlier. Earnings per share (EPS) came in at ₹0.84.
Operating profit stood at ₹5 crore — an operating margin (OPM) of 20.3%, compared with -2.0% in the year-ago quarter.
Full year and trailing twelve months
For the full year FY26, ANG Lifesciences India Ltd posted revenue of ₹92 crore, a growth of 1.9% over FY25, with a net loss of ₹5 crore.
On a trailing-twelve-month (TTM) basis, revenue stands at ₹92 crore with a net loss of ₹5 crore.
Valuation snapshot
At the current price of ₹36.50, 540694 has a market capitalisation of ₹47 crore.
Within the Pharmaceuticals industry, it is the 25th-largest of the 82 companies we track by market value.
Shareholding pattern
As of Mar 2026, promoters held 70.60%, public shareholders 29.40% of ANG Lifesciences India Ltd.